Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology

Inclusion Criteria:

- You must have Stage 3A or 3B Non-Small Cell Lung Cancer of the non-squamous type

- You must have measureable tumor lesions according to the Response Evaluation Criteria
in Solid Tumors (RECIST) guidelines or disease that can be evaluated on CT scan

- You must at least be able to physically be mobile, take care of yourself and must be
up and about and able to perform light activities such as light housework or office
work

- 18 years of age or older

- You have lost no more than 10% of body weight in the previous three months

- Women must be sterile, postmenopausal or on contraception and men must be sterile or
on contraception

- Your test results assessing the function of your blood forming tissue, kidneys, liver
and lungs are satisfactory

Exclusion Criteria:

- You cannot have other on-going illnesses including active infections, recent heart
problems or psychiatric illnesses

- You are unable to take vitamins (including injections of vitamin B12) or oral
cortisone medication

- You cannot have had a heart attack or other cardiac issues within 6 months of the
trial

- You cannot have received other investigational drugs within the last 30 days

- You are unable to stop taking more than 1.3 grams of aspirin on a daily basis or
non-steroidal anti-inflammatory agents.

- You cannot have had previous chest radiation, however, other prior radiation is
allowed if it was at least 30 days prior to the trial and limited in extent.

- You cannot have a radiation treatment plan that would expose more than 35% of your
unaffected lung to 20 Gy or more of radiation